anti-VEGF drugs


Also found in: Dictionary.

anti-VEGF drugs 

Drugs which bind to VEGF receptors without causing activation, thus blocking the production of new blood vessels and enhanced vessel permeability by the vascular endothelial growth factor (VEGF). They are used in the treatment of some forms of cancer (administered intravenously), and injected intravitreally in the treatment of choroidal neovascularization, retinal venous occlusion, and macular oedema. Examples: bevacizumab, pegaptanib sodium, ranibizumab. Syn. angiogenesis inhibitors. See age-related macular degeneration; diabetic retinopathy; VEGF.
References in periodicals archive ?
Presently, NICE criteria for the use of anti-VEGF drugs in the treatment of nAMD requires that the patient has signs of active disease, no permanent damage to the fovea, a lesion no larger than 12 times the optic disc area and visual acuity between 6/12 and 6/96.
After induction, intravitreal injections of anti-VEGF drugs were administered immediately in the ranibizumab group ( n = 30; ranibizumab 3 [micro]l, 10 mg/ml, Novartis Co.
9,10,11,12,15,16,17) Anti-VEGF drugs prevent the formation of new vasculature by directly affecting VEGF, but reducing retinal ischemia is not among their functions (Figure 1).
While some studies have shown that anti-VEGF drugs restrict blood and oxygen supplies--think angry tumor--others indicate that anti-VEGF drugs can plug leaks in blood vessels.
She needs anti-VEGF drugs to save her sight but the Dorset Trust has not yet provided the drugs, saying it has yet to formulate a policy for the treatment.
It is also notable that DCE-MRI results appear to show an anti-VEGF effect with ALN-VSP in approximately 50% of evaluable patients, including those who have been previously exposed to anti-VEGF drugs.
Dr Martin and his research team concluded that, despite such losses, anti-VEGF drugs offered a "major long-term therapeutic advantage" as more than half of patients had a visual acuity of 6/12 or better.
Retinal surgeons routinely inject anti-VEGF drugs such as Avastin, Lucentis and Eylea into the intravitreal space for wet macular degeneration and other vascular eye diseases.
In approximately 50% of evaluable patients, the average decline in Ktrans (measure of blood flow) in liver tumours where this parameter was measured was greater than or equal to 40%, an effect that is comparable to what has been observed with other anti-VEGF drugs in solid tumours.
The main reason for the controversy created by the off-label use of Avastin is that there are anti-VEGF drugs on the market that have formal approval for the treatment of AMD (and other eye conditions).
Nice (The National Institute for Clinical Excellence) has not yet given formal guidance on the anti-VEGF drugs, although they are available for use on the NHS if PCTs decided to fund them, says the Royal National Institute of the Blind.
In 62% of evaluable liver tumors, there was a greater than 40% decline in Ktrans (measure of blood flow), an effect that is comparable to what has been observed with other anti-VEGF drugs in solid tumors (Cannistra et al.